At 6.8% CAGR, the Middle East & Africa CIN & HR-HPV Treatment Market is projected to be worth US$ 742.37 million by 2028, says The Business Market Insights

According to the Business Market Insights’ research, the Middle East & Africa CIN & HR-HPV treatment market was valued at US$ 534.50 million in 2023 and is expected to reach US$ 742.37 million by 2028, registering a CAGR of 6.8% from 2023 to 2028. Use of modern technologies in CIN & HR-HPV screening and diagnosis and development and launch of innovative products are the critical factors attributed to the Middle East & Africa CIN & HR-HPV treatment market expansion.                    

Health authorities across the region recommend routine cervical cancer screenings to women as ~30% of the grade 3 CIN lesions develop into invasive cancers within 30 years. Slow progression provides several opportunities for detection and treatment. The manual cervical cancer screening methods are not always accurate, which results in skips in the detection of some lesions. Ongoing improvements in screening techniques are likely to increase cervical cancer detection rates and decrease mortality rates.

In 2021, the WHO Collaborating Centre for Cervical Cancer Elimination partnered with the University of Miami's Sylvester Comprehensive Cancer Centre, which will serve as a hub for research and technical assistance to help countries eliminate cervical cancer.

Thus, such technological advancements are likely to bring new trends in the CIN & HR-HPV market in the coming years.

On the contrary, Increased Reoccurrence Rate and High Cost of CIN & HR-HPV Treatment hurdles the growth of Middle East & Africa CIN & HR-HPV Treatment Market

Based on disease type, the Middle East & Africa CIN & HR-HPV treatment market is segmented into cervical intraepithelial neoplasia 1 (CIN 1), cervical intraepithelial neoplasia 2 (CIN 2), and cervical intraepithelial neoplasia 3 (CIN 3). The cervical intraepithelial neoplasia 3 (CIN 3) segment held 49.0% market share in 2023, amassing US$ 261.95 million. It is projected to garner US$ 378.69 million by 2028 to expand at 7.7% CAGR during 2023–2028.

Based on strain type, the Middle East & Africa CIN & HR-HPV treatment market is segmented into HPV 16, HPV 18, and others. The HPV 16 segment held 64.9% market share in 2023, amassing US$ 346.63 million. It is projected to garner US$ 482.19 million by 2028 to expand at 6.8% CAGR during 2023–2028.

Based on offering, the Middle East & Africa CIN & HR-HPV treatment market is bifurcated into diagnostic methods and treatments. The treatments segment held 72.4% market share in 2023, amassing US$ 387.23 million. It is projected to garner US$ 524.21 million by 2028 to expand at 6.2% CAGR during 2023–2028. Further, diagnostic methods are segmented into pap smear, HPV testing, colposcopy, and biopsy. Further, treatments are bifurcated into excision surgery and ablation techniques.

Based on product type, the Middle East & Africa CIN & HR-HPV treatment market is segmented into kits & reagents, instruments, and services. The services segment held 60.6% market share in 2023, amassing US$ 323.86 million. It is projected to garner US$ 452.14 million by 2028 to expand at 6.9% CAGR during 2023–2028.

Based on end user, the Middle East & Africa CIN & HR-HPV treatment market is segmented into hospitals & clinics, diagnostic laboratories, specialized clinical laboratories, and others. The hospitals & clinics segment held 49.7% market share in 2023, amassing US$ 265.79 million. It is projected to garner US$ 363.98 million by 2028 to expand at 6.5% CAGR during 2023–2028.

Based on country, the Middle East & Africa CIN & HR-HPV treatment market has been categorized into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa.  Our regional analysis states that South Africa captured 37.4% market share in 2023. It was assessed at US$ 200.08 million in 2023 and is likely to hit US$ 283.32 million by 2028, exhibiting a CAGR of 7.2% during the forecast period.     

Key players dominating the Middle East & Africa CIN & HR-HPV treatment market are Fujirebio Europe NV; Qiagen NV; Abbott Laboratories; F. Hoffmann-LA Roche Ltd; and Thermo Fisher Scientific Inc among others.   

• In Oct 2022, Fujirebio Europe receives distribution rights.
• In Sept 2020, Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com